⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CGEM News
Cullinan Therapeutics, Inc. Common Stock
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
businesswire.com
CGEM
Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
globenewswire.com
CGEM
Form 8-K
sec.gov
CGEM
Form 8-K
sec.gov
CGEM
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
globenewswire.com
CGEM
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
globenewswire.com
CGEM
Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML
globenewswire.com
CGEM
Form 8-K
sec.gov
CGEM
Form 8-K
sec.gov
CGEM
Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases
globenewswire.com
CGEM